Fiduciary Alliance LLC Buys 4,828 Shares of Vertex Pharmaceuticals

The investment firm added to its position in the pharmaceutical company during Q4

Apr. 11, 2026 at 7:53am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex, industrial-looking mechanism with gears, levers, and other components in shades of grey, conceptually representing the financial infrastructure and institutional power behind pharmaceutical innovation.

Fiduciary Alliance's increased investment in Vertex Pharmaceuticals signals confidence in the biotech firm's ability to drive growth through its innovative drug pipeline.Boston Today

Fiduciary Alliance LLC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company's recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,828 shares of the pharmaceutical company's stock, valued at approximately $2,189,000.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology company focused on developing innovative treatments for serious diseases, particularly cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many CF patients. Fiduciary Alliance's investment in Vertex reflects the firm's confidence in the company's growth potential and pipeline.

The details

According to the 13F filing, Fiduciary Alliance LLC purchased 4,828 shares of Vertex Pharmaceuticals during the fourth quarter. This new position was valued at approximately $2,189,000. The investment comes as Vertex continues to expand its cystic fibrosis treatments and explore new therapeutic areas. Vertex's stock has seen strong performance, with the share price rising over 20% in the past year.

Fiduciary Alliance LLC purchased the Vertex Pharmaceuticals shares during the fourth quarter of 2025.

The players